Marisa Wexler, MS,  senior science writer—

Several novel mutations in aminoacyl-tRNA synthetase (ARS) genes were linked with Charcot-Marie-Tooth disease (CMT) in a recent study out of Korea. “This study will be useful for performing exact molecular diagnoses and providing reference data for other population studies,” its researchers wrote. The study, “Variants of…

The CMT Research Foundation has awarded nearly $100,000 to support a project that is seeking a better way to deliver treatments to peripheral nerve tissue. “If successful, this work will provide the evidence for further development of this novel approach to overcoming the drug delivery challenge in CMT,” Susan…

The Hereditary Neuropathy Foundation, known as HNF, is joining forces with Rarebase, a biotech company, on a project that aims to identify potential treatments for multiple different types of Charcot-Marie-Tooth disease (CMT). It is the first research initiative to tackle multiple types of CMT in one project,…

A new podcast called “CMT 4 Me,” launched by the patient-led Charcot-Marie-Tooth Association, aims to give a voice to people living with Charcot-Marie-Tooth disease (CMT), and to raise awareness of the rare disorder. Its creators hope the format will provide a new outlet for patients and supporters who may…

Scientists have developed a new animal model of X-linked Charcot-Marie-Tooth disease type 6, or CMTX6, which is caused by a mutation in the gene PDK3. This new worm model — the first for CMTX6 in a living organism, according to researchers — may provide insights into treatment approaches…

InFlectis BioScience and the University of Chicago have entered into an agreement that grants InFlectis exclusive patent rights to use a family of small molecules as potential treatments for demyelinating disorders that include Charcot-Marie-Tooth disease (CMT). Specifically, the license covers the use of IFB-088 and IFB-048,…

A new financial partnership between Pharnext and Alpha Blue Ocean will help support the Phase 3 clinical trial PREMIER, which is testing Pharnext’s investigational therapy PXT3003 for Charcot-Marie-Tooth disease type 1A (CMT1A). CMT1A is the most common subtype of CMT type 1, which is the most common…

Eurordis opened a campaign, called Rare 2030 Action, that is seeking to establish a European action plan for rare diseases to ensure that none of the 30 million people in Europe living with rare diseases are left behind by the start of a new decade. As part of…

Augustine Therapeutics has received €1.2 million (about $1.4 million) in funding for a research project that will seek to further characterize the biology of Charcot-Marie-Tooth disease (CMT), and to investigate potential treatments. The funding was awarded by the Flanders Agency for Innovation and Entrepreneurship (VLAIO), in Belgium. “This…

More research is needed into whether different types of exercise can provide benefits to people with Charcot-Marie-Tooth disease (CMT), and how exercise affects biological processes related to CMT, a review states. The article, “Charcot-Marie-Tooth Disease: Genetic Predisposition and Effect of Resistance Training, Endurance Training, Physical Activity…